KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Amortization of Deferred Charges: 2011-2020

Historic Amortization of Deferred Charges for Biocryst Pharmaceuticals (BCRX) over the last 10 years, with Dec 2020 value amounting to $2.4 million.

  • Biocryst Pharmaceuticals' Amortization of Deferred Charges changed negligibly% to $110,000 in Q4 2015 from the same period last year, while for Dec 2015 it was $440,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.4 million for FY2020, which is 89.98% up from last year.
  • As of FY2020, Biocryst Pharmaceuticals' Amortization of Deferred Charges stood at $2.4 million, which was up 89.98% from $1.3 million recorded in FY2019.
  • Biocryst Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $2.4 million during FY2020, with a 5-year trough of $558,000 in FY2016.
  • Its 3-year average for Amortization of Deferred Charges is $1.5 million, with a median of $1.3 million in 2019.
  • Data for Biocryst Pharmaceuticals' Amortization of Deferred Charges shows a peak YoY spiked of 89.98% (in 2020) over the last 5 years.
  • Over the past 5 years, Biocryst Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $558,000 in 2016, then surged by 56.99% to $876,000 in 2017, then rose by 1.03% to $885,000 in 2018, then spiked by 44.41% to $1.3 million in 2019, then surged by 89.98% to $2.4 million in 2020.